Revenue: As of FY2025 Q2, the actual value is USD 6.046 M, beating the estimate of USD 3.455 M.EPS: As of FY2025 Q2, the actual value is USD -0.008.EBIT: As of FY2025 Q2, the actual value is USD -3.664 M, missing the estimate of USD -1.804 M.<h3>ONM Environmental</h3><ul><li>Revenue: $2,006,000 (Q2 2025), $4,809,000 (H1 2025) compared to $4,012,000 (Q2 2024), $8,586,000 (H1 2024).</li><li>Cost of Goods Sold: 45% (Q2 2025), 50% (H1 2025) compared to 55% (Q2 2024), 54% (H1 2024).</li><li>SG&amp;A Expense: Decreased 14% (Q2 2025), 7% (H1 2025).</li><li>Operating Income: $823,000 (Q2 2025), $1,780,000 (H1 2025) compared to $1,490,000 (Q2 2024), $3,288,000 (H1 2024).</li></ul><h3>BLEST (Engineering)</h3><ul><li>Revenue: $771,000 (Q2 2025), $1,237,000 (H1 2025) compared to $1,259,000 (Q2 2024), $1,615,000 (H1 2024).</li><li>Cost of Revenues: 58% (Q2 2025), 67% (H1 2025) compared to 67% (Q2 2024), 62% (H1 2024).</li><li>SG&amp;A Expense: $224,000 (Q2 2025), $556,000 (H1 2025) compared to $238,000 (Q2 2024), $441,000 (H1 2024).</li><li>Operating Income (Loss): $16,000 (Q2 2025), -$364,000 (H1 2025) compared to -$247,000 (Q2 2024), -$692,000 (H1 2024).</li></ul><h3>Clyra Medical</h3><ul><li>Revenue: None.</li><li>Total Costs and Expenses: $1,263,000 (Q2 2025), $2,580,000 (H1 2025) compared to $616,000 (Q2 2024), $1,154,000 (H1 2024).</li><li>R&amp;D Expenses: $229,000 (Q2 2025), $564,000 (H1 2025) compared to $100,000 (Q2 2024), $213,000 (H1 2024).</li></ul><h3>BETI</h3><ul><li>Revenue: None.</li><li>Total Costs and Expenses: $122,000 (Q2 2025), $217,000 (H1 2025) compared to $226,000 (Q2 2024), $388,000 (H1 2024).</li><li>R&amp;D Expenses: $54,000 (Q2 2025), $113,000 (H1 2025) compared to $133,000 (Q2 2024), $220,000 (H1 2024).</li></ul><h3>BEST</h3><ul><li>Revenue: None.</li><li>Total Costs and Expenses: $67,000 (Q2 2025), $125,000 (H1 2025) compared to $49,000 (Q2 2024), $115,000 (H1 2024).</li></ul><h3>BioLargo Canada</h3><ul><li>Revenue: None.</li><li>Total Costs and Expenses: $144,000 (Q2 2025), $300,000 (H1 2025) compared to $118,000 (Q2 2024), $223,000 (H1 2024).</li></ul><h3>Consolidated</h3><ul><li>SG&amp;A Expense: $2,688,000 (Q2 2025), $5,250,000 (H1 2025) compared to $2,404,000 (Q2 2024), $4,629,000 (H1 2024).</li><li>R&amp;D Expense: $535,000 (Q2 2025), $1,325,000 (H1 2025) compared to $623,000 (Q2 2024), $1,407,000 (H1 2024).</li><li>Interest Expense: $80,000 (Q2 2025), $145,000 (H1 2025) compared to $2,000 (Q2 2024), $14,000 (H1 2024).</li><li>Net Loss: $1,882,000 (Q2 2025), $3,803,000 (H1 2025) compared to $780,000 (Q2 2024), $1,555,000 (H1 2024).</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: BioLargo aims to increase revenues, generate cash from operations, and/or generate cash from financing activities. The company is also focused on converting assets such as accounts receivable and note receivable into cash.</li><li>Non-Core Business: The company is exploring multiple opportunities to commercialize its proprietary liquid sodium batteries through joint ventures with third parties. BioLargo would receive a minority equity position in each joint venture, manufacture and sell proprietary battery components, and receive a royalty on the revenues of the joint venture.</li><li>Priority: Emphasis on securing larger contracts for PFAS treatment and other water treatment technologies, and leveraging partnerships to accelerate adoption of the AEC technology.</li></ul>

BioLargo, Inc. | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 6.046 M